Methylphenidate versus placebo for treating fatigue in patients with advanced cancer: randomized, double-blind, multicenter, placebo-controlled trial

HIGHLIGHTS

  • What: Sample Size With 162-230 randomly assigned and 130-172 evaluable patients (20%-25% attrition), this study had 80%-90% power to detect five-point difference on FACIT-F (effect size 0.5) at 6 6 2 weeks between groups at 5% significance (two sided). The authors report P values for the randomized group with estimate and 95% CI. All nominally significant differences in secondary outcomes should be regarded as exploratory findings as the study was not powered to look for such differences and no correction was made for multiple analyses.
  • Who: Patrick Charles . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?